Anne Mercier-Blas Selected Research

Bevacizumab (Avastin)

1/2022

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anne Mercier-Blas Research Topics

Disease

1	Neoplasm Metastasis (Metastasis) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019

Drug/Important Bio-Agent (IBA)

1	folfirinoxIBA 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2022
1	liposomal doxorubicin (Doxil)FDA Link 01/2019
1	Carboplatin (JM8)FDA LinkGeneric 01/2019
1	PlatinumIBA 01/2019

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 01/2022
1	Therapeutics 01/2022